Author: admin

Personalized Longevity Company Qyral Expands its Services to Puerto Rico

Personalized Longevity Company Qyral Expands its Services to Puerto Rico
The expansion will introduce personalized weight management solutions and open new opportunities for local consultants.

Qyral, a leading provider of personalized healthcare solutions, has announced the expansion of its services to Puerto Rico, introducing not only innovative weight management options but also opening new avenues for entrepreneurship through its consultant network.

The expansion brings Qyral’s personalized weight management approach to the island, offering both prescription Semaglutide and Tirzepatide on its platform. Clinical trials have shown these medications to result in significant weight loss, among other health benefits. Qyral’s unique program personalizes these solutions to individual health profiles and goals, offering comprehensive support and guidance.

“Our arrival in Puerto Rico represents an exciting milestone for Qyral,” says Hanieh Sigari, CEO and Founder of Qyral. “We are thrilled to help empower individuals across Puerto Rico to transform their lives with our personalized services.”

As part of its strategic expansion, Qyral is also now accepting new consultants in Puerto Rico. This move enables the company to broaden its footprint in the wellness industry and connect with a new audience eager for advanced weight management solutions.

Jennifer Harmon, Chief Sales Officer at Qyral, says, “This expansion will play a crucial role in introducing our products to a wider community. We’re looking forward to seeing the positive impact our consultants will have in helping individuals achieve their wellness goals.”

Puerto Rican customers can now visit www.Qyral.com to connect with a licensed provider and get personalized weight management solutions. They can also access the website to sign up as a Qyral Consultant.

About Qyral

Qyral was founded in 2019 with the mission of helping people age well and live well. Since then, it has grown to a personalized longevity company that offers prescription and non-prescription skincare and weight management solutions. For more information about Qyral, visit www.Qyral.com.

Media Contact
Company Name: Qyral
Contact Person: Olha Ivasiuk
Email: Send Email
Phone: 855-496-0655
Country: United States
Website: https://www.qyral.com/

International Number One Bestseller About Belief In God Avoids “Religion”

Imagine 70 International Thought Leaders – scientists, engineers, political leaders, journalists, corporate leaders, artists, media influencers, professors, even former atheists – all answering a simple yet profound question in 500 words or less:
“Why do you believe in a God?“

“Why do you believe in a God?“

In today’s world, why should anyone believe in God? At a time when church membership is falling and the world seems to be skidding off the rails, this question launched a quest, and that quest has become a runaway bestseller… for skeptics AND believers alike.

That’s what happened when the editors of Elevator Pitches for God: 70 One-Page Essays by Thought Leaders On Why They Believe offered each author a single page on which to share their personal spiritual journey, to reveal how they arrived at their conclusion that God exists, and how it affects their daily life.

“We sought out interesting, thoughtful people with a wide range of backgrounds and experiences,” says Ron Kardos, one of the two editors along with Bruce Licht, who added, “We didn’t give the authors any direction about what to write. They all had their own ideas about how to approach the subject. We didn’t know what they were going to discuss until we received their essays.”

“There seems to be a groundswell of interest and a real need for a non-religious conversation about God. The world is desperate for meaning, purpose, and wisdom; a glance at social media will show you that the struggle is real.”

Proceeds will go to support For Good and For All, Inc., a non-profit 501(c)(3) media platform that is not political in any way, whose mission is to facilitate frank discussions about important issues that matter to humankind: https://EP4G.com

Feedback from readers reflects the power of this approach:

“At last! A book about God that won’t turn off skeptics. This book is for people who wonder ‘Why do so many people believe in God?’”

“A fascinating read. It has so many different perspectives from so many different people. You’re sure to find many essays that talk to you about why well-known and thoughtful people accept God.”

“They… approach the topic from every conceivable perspective (e.g., science, nature, and art) and a range of religious backgrounds (including Christianity, Islam, and Judaism).”

“There is no effort to turn the skeptic into a believer and certainly not to promote any religion. So it is a very “safe” book for both skeptics and believers to have in the home.”

Elevator Pitches for God: 70 One-Page Essays by Thought Leaders On Why They Believe is available in Kindle, hardcover, and audiobook editions on Amazon and at For Good and For All, Inc. (ep4g.com)

About the authors

Ron Kardos

Ron grew up in Los Angeles and graduated from UCLA with a BA in Economics. After college, Ron and his college roommate started businesses in autos, finance, and real estate. A spiritual late bloomer, Ron devotes much of his time to learning.

Bruce Licht

Bruce grew up in Lafayette, California and received a BA in Political Science from UCLA, and a Graduate Gemologist degree from the Gemological Institute of America. After graduating, Bruce operated his family’s retail business for twenty-two years before changing careers and joining a national technical publishing company for seventeen years, serving as the company’s publisher.

For more information or to contact the authors directly,

(650) 533-0675

Books are available at special discounts when purchased in bulk for sales promotion, fundraising, or educational use. Special editions can also be created to specifications. For sales inquiries, contact us at the address below or email us at: sales@ep4g.com.

For all permission requests, please contact us in writing at the address below or email us at: permissions@ep4g.com

For all other information, contact: info@ep4g.com.

Media Contact
Company Name: For Good and For All, Inc.
Contact Person: Ron Kardos or Bruce Licht
Email: Send Email
Phone: (650) 533-0675
Country: United States
Website: https://EP4G.com

Empowering Tech: Africa’s Untapped Talent and ProDevs’ Impact

The question often heard is, “Why should one hire from Africa?”

It’s not just a question; it’s a revelation that unveils a world of untapped potential. In an era where the hunger for skilled professionals is insatiable, the global talent shortage is predicted to reach a staggering 4.3 million workers by 2030, according to the visionary insights of Korn Ferry International.

As companies worldwide grapple with this impending crisis, an unexpected hero emerges – Africa. Let’s not just talk strategy; let’s embark on a transformative journey to understand why hiring tech talents from Africa is not merely a decision; it’s a game-changer.

Unlocking Africa’s Tech Potential

Africa’s tech market beats with a remarkable 15-20% annual growth rate, harboring seven billion-dollar startups. Within its 54 countries lie diverse tech ecosystems, overcoming infrastructure hurdles through mobile adaptability, giving rise to innovations in fintech, e-commerce, and m-health.

Africa’s tech talent, spanning software development, AI/ML, cybersecurity, and digital marketing, isn’t just proficient; it’s excellent. Giants like Nigeria, Egypt, and South Africa host the largest tech talent pools, offering a sweet spot of cost-effectiveness. The continent nurtures a diverse skill set showcased through events like the Africa Tech Exhibition in Lagos.

The Promise Within Africa’s Youth

Africa’s youth is more than just a number; it’s a promise of future tech talent. The continent’s cost-effectiveness, diverse skill set, innovation, and adaptability present opportunities for companies to tap into untapped potential. Africa isn’t just catching up; it’s a garden waiting to bloom.

ProDevs: Pioneering Change

Founded in 2018, ProDevs aimed to simplify product development for startups but soon recognized the industry’s talent gap. William Nwogbo, ProDevs’ founder, speaks of the company’s commitment to innovation. Thriving on problem-solving, ProDevs launched a groundbreaking product in 2020 connecting talents across Africa to global and local opportunities.

Since its inception, ProDevs has been instrumental in providing over 200+ talents with access to new and exciting opportunities. Working with prominent startups and corporations such as Dukka, Sterling Bank, Coronation Group, PayHippo and more, have solidified ProDevs’ commitment to its overarching goal: opening doors of opportunity for African tech talents.

ProDevs isn’t just a company; it’s a catalyst for change in the tech realm. Guided by William Nwogbo’s vision, the company reshapes how talent is harnessed. The commitment to innovation propels ProDevs toward ProDevsAI, expanding opportunities for the talented individuals in their pool. The horizon extends further as they aim to broaden their client network into North America, with a bold goal of securing 350 new job placements in 2024.

Challenges: Turning Tables in Tech

ProDevs acknowledges and navigates challenges such as skill gaps, infrastructure limitations, visa complexities, cultural differences, and political and economic instability. Instead of roadblocks, ProDevs sees opportunities for innovation and resilience, turning uncertainties into fuel for creative solutions.

Africa: A Beacon of Innovation

Africa isn’t just a continent; it’s a testament to what happens when potential meets opportunity. Hiring tech talents from Africa isn’t just a choice; it’s an investment. It’s a journey into a future where challenges are met with resilience, diversity is a driving force, and untapped potential becomes the cornerstone of global innovation. Welcome to the revolution!

Hiring today?

Send an email to business@prodevs.io or visit the website at https://prodevs.io (Signup as a client)

Schedule a call with ProDevs: https://calendly.com/prodevs-207/30min

OFFICE_ADDRESS

651 N Broad St. Suite 206, Middletown, DE 19709, USA

89 Monaco Street Brampton Ontario, L7A 1X2

2nd Floor, 10 Hughes Avenue, Alagomeji, Yaba, Lagos, Nigeria.

 

 

Media Contact
Company Name: ProDevs Outsourcing Ltd
Email: Send Email
Phone: +234 703 944 8968
Country: United States
Website: https://www.prodevs.io/

Dry Age Macular Degeneration Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Janssen Research, Belite Bio, Katairo

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dry Age Macular Degeneration pipeline constitutes 58+ key companies continuously working towards developing 64+ Dry Age Macular Degeneration treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 The Dry Age Macular Degeneration Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Dry Age Macular Degeneration Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dry Age Macular Degeneration Market.

 

Some of the key takeaways from the Dry Age Macular Degeneration Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies with a considerable amount of success over the years. 
  • Dry Age Macular Degeneration companies working in the treatment market are Eyevensys, SanBio, Nanoscope Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Allegro Ophthalmics, Gyroscope Therapeutics, IVERIC bio, Alkeus Pharmaceuticals, Gemini Therapeutics, Eyestem, OliX Pharmaceuticals, and others, are developing therapies for the Dry Age Macular Degeneration treatment 
  • Emerging Dry Age Macular Degeneration therapies in the different phases of clinical trials are- EYS809, SB-623, MCO-020, RPESC RPE 4W, CPCB-RPE1, Risuteganib, GT005, Zimura, ALK-001, GEM103, Eyecyte RPE, OLX301A, EYS809, and others are expected to have a significant impact on the Dry Age Macular Degeneration market in the coming years.   
  • In November 2022, IVERIC Bio announced that the U.S. Food and Drug Administration (FDA) has grantedBreakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novelinvestigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to AgeRelated Macular Degeneration (AMD).
  • Out of the emerging Dry Age-related Macular Degeneration therapies Eyecyte RPE (Eyestem), OLX301A (OliX Pharmaceuticals), and EYS809 (Eyevensys) are in the early stages of development for Dry AMD treatment.
  • On January 13, 2022, ONL Therapeutics, announced that it had closed on its second tranche of the Company’s Series B financing. The total proceeds raised in Series B was USD 46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD.

 

Dry Age Macular Degeneration Overview

Dry age-related macular degeneration (AMD) involves a gradual breakdown of macular cells over an extended period. This occurs as retinal cells decline without renewal. It’s important to note that the term ‘dry’ doesn’t imply dry eyes but rather distinguishes it from wet AMD.

 

Get a Free Sample PDF Report to know more about Dry Age Macular Degeneration Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/dry-age-macular-degeneration-pipeline-insight

 

Emerging Dry Age Macular Degeneration Drugs Under Different Phases of Clinical Development Include:

  • EYS809: Eyevensys
  • SB-623: SanBio
  • MCO-020: Nanoscope Therapeutics
  • RPESC RPE 4W : Luxa Biotechnology
  • CPCB-RPE1: Regenerative Patch Technologies
  • Risuteganib: Allegro Ophthalmics
  • GT005: Gyroscope Therapeutics
  • Zimura: IVERIC bio
  • ALK-001: Alkeus Pharmaceuticals
  • GEM103: Gemini Therapeutics
  • Eyecyte RPE: Eyestem
  • OLX301A: OliX Pharmaceuticals
  • EYS809: Eyevensys

 

Dry Age Macular Degeneration Route of Administration

Dry Age Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Dry Age Macular Degeneration Molecule Type

Dry Age Macular Degeneration Products have been categorized under various Molecule types, such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Dry Age Macular Degeneration Pipeline Therapeutics Assessment

  • Dry Age Macular Degeneration Assessment by Product Type
  • Dry Age Macular Degeneration By Stage and Product Type
  • Dry Age Macular Degeneration Assessment by Route of Administration
  • Dry Age Macular Degeneration By Stage and Route of Administration
  • Dry Age Macular Degeneration Assessment by Molecule Type
  • Dry Age Macular Degeneration by Stage and Molecule Type

 

DelveInsight’s Dry Age Macular Degeneration Report covers around 64+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Dry Age Macular Degeneration product details are provided in the report. Download the Dry Age Macular Degeneration pipeline report to learn more about the emerging Dry Age Macular Degeneration therapies

 

Some of the key companies in the Dry Age Macular Degeneration Therapeutics Market include:

Key companies developing therapies for Dry Age Macular Degeneration are – Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, and others.

 

Dry Age Macular Degeneration Pipeline Analysis:

The Dry Age Macular Degeneration pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Dry Age Macular Degeneration with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dry Age Macular Degeneration Treatment.
  • Dry Age Macular Degeneration key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Dry Age Macular Degeneration Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dry Age Macular Degeneration market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Dry Age Macular Degeneration drugs and therapies

 

Dry Age Macular Degeneration Pipeline Market Drivers

  • Growing geriatric population and rising prevalence of AMD, robust pipeline for dry AMD treatment are some of the important factors that are fueling the Dry Age Macular Degeneration Market.

 

Dry Age Macular Degeneration Pipeline Market Barriers

  • However, lack of awareness about dry AMD, lengthy and expensive clinical trials, lack of early detection and other factors are creating obstacles in the Dry Age Macular Degeneration Market growth.

 

Scope of Dry Age Macular Degeneration Pipeline Drug Insight    

  • Coverage: Global
  • Key Dry Age Macular Degeneration Companies: Eyevensys, SanBio, Nanoscope Therapeutics, Luxa Biotechnology, Regenerative Patch Technologies, Allegro Ophthalmics, Gyroscope Therapeutics, IVERIC bio, Alkeus Pharmaceuticals, Gemini Therapeutics, Eyestem, OliX Pharmaceuticals, and others
  • Key Dry Age Macular Degeneration Therapies: EYS809, SB-623, MCO-020, RPESC RPE 4W, CPCB-RPE1, Risuteganib, GT005, Zimura, ALK-001, GEM103, Eyecyte RPE, OLX301A, EYS809, and others
  • Dry Age Macular Degeneration Therapeutic Assessment: Dry Age Macular Degeneration current marketed and Dry Age Macular Degeneration emerging therapies
  • Dry Age Macular Degeneration Market Dynamics: Dry Age Macular Degeneration market drivers and Dry Age Macular Degeneration market barriers 

 

Request for Sample PDF Report for Dry Age Macular Degeneration Pipeline Assessment and clinical trials

 

Table of Contents

1. Dry Age Macular Degeneration Report Introduction

2. Dry Age Macular Degeneration Executive Summary

3. Dry Age Macular Degeneration Overview

4. Dry Age Macular Degeneration- Analytical Perspective In-depth Commercial Assessment

5. Dry Age Macular Degeneration Pipeline Therapeutics

6. Dry Age Macular Degeneration Late Stage Products (Phase II/III)

7. Dry Age Macular Degeneration Mid Stage Products (Phase II)

8. Dry Age Macular Degeneration Early Stage Products (Phase I)

9. Dry Age Macular Degeneration Preclinical Stage Products

10. Dry Age Macular Degeneration Therapeutics Assessment

11. Dry Age Macular Degeneration Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Dry Age Macular Degeneration Key Companies

14. Dry Age Macular Degeneration Key Products

15. Dry Age Macular Degeneration Unmet Needs

16 . Dry Age Macular Degeneration Market Drivers and Barriers

17. Dry Age Macular Degeneration Future Perspectives and Conclusion

18. Dry Age Macular Degeneration Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dry Age Macular Degeneration Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight |Janssen Research, Belite Bio, Katairo

Alamaula LLC Launches in the United States, Creating Unparalleled Online Shopping With Global Accessibility and Worldwide Shipping

After an eventful history, Alamaula LLC relaunched in the United States under the leadership of Matias Gemelli, an Argentine entrepreneur in the construction and technology sectors. The company prides itself on creating exceptional online shopping experiences with unparalleled customer satisfaction while providing global accessibility. 

After an eventful history since its founding, Alamaula started 2024 by launching in the United States. The company was founded in 2009 in Argentina. It quickly grew to become a substantial online marketplace that reliably combined quality products, durability, and unique designs. The company was acquired by eBay in 2011. It continued the trend of growth and innovation. Unfortunately, eBay announced its shutdown in 2019. Matias Gemelli is currently at the helm of Alamaula LLC and led the company to its US launch. 

“We’re committed to an unparalleled shopping experience, emphasizing customer satisfaction and global accessibility,” Gemelli said. 

Alamaula’s online store offers more than 30,000 products with free worldwide shipping on many of them. The company’s website is a one-stop shop for many popular trends, furniture, home decorative items, and more. Alamaula is the premier destination for easy online shopping, where customers can find everything they need to spruce up their home and garden with new decor or gadgets.

Discover the latest trends at the Alamaula clothing store, where the most recent styles in clothes and accessories are available. Find thousands of fashion options keeping with the latest trends and the pieces necessary to build the perfect outfit. 

Alamaula was created with a mission to be the destination where quality and variety meet. The company’s vast selection includes the latest trends in everything from fashion to home gadgets. Products are meticulously selected from trusted manufacturers to ensure everything meets the company’s high standards. Alamaula offers a wide array of high-quality gadgets to make one’s life or home more comfortable. 

“We ensure a shopping experience that is not just satisfying but also seamlessly convenient,” Gemelli said. “At Alamaula, every click brings you closer to finding exactly what you need, delivered right to your doorstep.”

Customers can expect a staggering variety in the offerings at Alamaula. The curated collections are divided into categories, including fashion and accessories to stay ahead of the trends, home electronics and gadgets to upgrade to the latest technology, kitchen essentials to inspire culinary creativity, outdoor and garden supplies to transform outdoor spaces, and pet supplies to pamper furry friends. 

“At Alamaula, quality is not just a word; it’s our promise to you,” Gemelli said. “Whether you’re browsing for trendy apparel, the latest electronics, or home essentials, rest assured that quality is at the heart of everything we offer.”

Creating positive customer experiences is at the heart of Alamaula’s company philosophy. The user-friendly website simplifies and streamlines online shopping with easy navigation, detailed product descriptions, and clear imagery that shows customers what to expect when they purchase. 

Customer service is a priority for Alamaula. The responsive staff is always available and ready to assist customers with any questions or concerns they may have. The company also utilizes the latest security technology to ensure customers’ information remains secure so they can shop without worries. 

One of the core goals at Alamaula is to make online shopping globally accessible. It works toward this aim by offering free shipping worldwide on many of the thousands of products it sells. Customers can enjoy safe shopping and fast delivery with trusted couriers when they shop with Alamaula. The company creates worry-free shopping with a money-back guarantee and a no-questions-asked return policy. 

Alamaula operates a blog with regular updates about industry trends, company updates, and information about the latest popular products. It also provides a newsletter that allows customers to be the first to know about new product arrivals, exclusive offers, and more. 

The leadership team at Alamaula reports that the company’s core values are centered around creating a company culture that encourages an adventurous, creative, and open-minded attitude. The team actively works to develop long-term relationships with its customers while pursuing growth and learning. Alamaula seeks to inspire happiness and positivity by doing everything in its power to ensure customers are pleased with every interaction.

Alamaula team is continuously working on its online store and welcomes suggestions from customers on how it can improve the shopping experience. Those with questions or proposals are invited to contact Alamaula’s team to share their ideas. 

Visit the Alamaula LLC website to learn more about the company’s versatile offerings and secure online store. Reach out and connect with the brand through social media on  Facebook, Instagram, and Pinterest to get inspired by the latest trends, products, and exclusive offers. 

Media Contact
Company Name: ALAMAULA, LLC
Contact Person: Matias Gemelli
Email: Send Email
Address:7345 W SAND LAKE RD, STE 210 OFFICE 2382
City: ORLANDO
State: FL 32819
Country: United States
Website: https://alamaula.com

Pre-Eclampsia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Pre-Eclampsia pipeline constitutes 4+ key companies continuously working towards developing 4+ Pre-Eclampsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Pre-Eclampsia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Pre-Eclampsia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pre-Eclampsia Market.

 

Some of the key takeaways from the Pre-Eclampsia Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Pre-Eclampsia treatment therapies with a considerable amount of success over the years. 
  • Pre-Eclampsia companies working in the treatment market are Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others, are developing therapies for the Pre-Eclampsia treatment 
  • Emerging Pre-Eclampsia therapies in the different phases of clinical trials are- GMA-312, C 103, CBP-4888, KW-3357, and others are expected to have a significant impact on the Pre-Eclampsia market in the coming years.  
  • KW-3357 is an antithrombin (AT) medication developed using recombinant DNA technology and precise control over sugar-chain composition. It is a recombinant AT formulation designed to possess an identical amino acid sequence and sugar chain structure as natural human AT.

 

Pre-Eclampsia Overview

Pre-eclampsia is a serious pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most commonly the liver and kidneys. It typically occurs after the 20th week of pregnancy and can affect both the mother and the unborn baby.

 

Get a Free Sample PDF Report to know more about Pre-Eclampsia Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/pre-eclampsia-pipeline-insight

 

Emerging Pre-Eclampsia Drugs Under Different Phases of Clinical Development Include:

  • GMA-312: Gmax Biopharm
  • C 103: Vicore Pharma
  • CBP-4888: Comanche Biopharma
  • KW-3357: Kyowa Kirin

 

Pre-Eclampsia Route of Administration

Pre-Eclampsia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Pre-Eclampsia Molecule Type

Pre-Eclampsia Products have been categorized under various Molecule types, such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Pre-Eclampsia Pipeline Therapeutics Assessment

  • Pre-Eclampsia Assessment by Product Type
  • Pre-Eclampsia By Stage and Product Type
  • Pre-Eclampsia Assessment by Route of Administration
  • Pre-Eclampsia By Stage and Route of Administration
  • Pre-Eclampsia Assessment by Molecule Type
  • Pre-Eclampsia by Stage and Molecule Type

 

DelveInsight’s Pre-Eclampsia Report covers around 4+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Pre-Eclampsia product details are provided in the report. Download the Pre-Eclampsia pipeline report to learn more about the emerging Pre-Eclampsia therapies

 

Some of the key companies in the Pre-Eclampsia Therapeutics Market include:

Key companies developing therapies for Pre-Eclampsia are – Kyowa Kirin, Gmax Biopharm, Vicore Pharma, and others.

 

Pre-Eclampsia Pipeline Analysis:

The Pre-Eclampsia pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.
  • Pre-Eclampsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Pre-Eclampsia drugs and therapies

 

Pre-Eclampsia Pipeline Market Drivers

  • Increasing women population suffering from Pre-Eclampsia, growing focus on the development of innovative Pre-Eclampsia diagnostic products are some of the important factors that are fueling the Pre-Eclampsia Market.

 

Pre-Eclampsia Pipeline Market Barriers

  • However, high cost associated with the treatment of Pre-Eclampsia, lack of awareness among patients regarding the disease and other factors are creating obstacles in the Pre-Eclampsia Market growth.

 

Scope of Pre-Eclampsia Pipeline Drug Insight    

  • Coverage: Global
  • Key Pre-Eclampsia Companies: Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin, and others
  • Key Pre-Eclampsia Therapies: GMA-312, C 103, CBP-4888, KW-3357, and others
  • Pre-Eclampsia Therapeutic Assessment: Pre-Eclampsia current marketed and Pre-Eclampsia emerging therapies
  • Pre-Eclampsia Market Dynamics: Pre-Eclampsia market drivers and Pre-Eclampsia market barriers 

 

Request for Sample PDF Report for Pre-Eclampsia Pipeline Assessment and clinical trials

 

Table of Contents

1. Pre-Eclampsia Report Introduction

2. Pre-Eclampsia Executive Summary

3. Pre-Eclampsia Overview

4. Pre-Eclampsia- Analytical Perspective In-depth Commercial Assessment

5. Pre-Eclampsia Pipeline Therapeutics

6. Pre-Eclampsia Late Stage Products (Phase II/III)

7. Pre-Eclampsia Mid Stage Products (Phase II)

8. Pre-Eclampsia Early Stage Products (Phase I)

9. Pre-Eclampsia Preclinical Stage Products

10. Pre-Eclampsia Therapeutics Assessment

11. Pre-Eclampsia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pre-Eclampsia Key Companies

14. Pre-Eclampsia Key Products

15. Pre-Eclampsia Unmet Needs

16 . Pre-Eclampsia Market Drivers and Barriers

17. Pre-Eclampsia Future Perspectives and Conclusion

18. Pre-Eclampsia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pre-Eclampsia Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Gmax Biopharm, Vicore Pharma, Comanche Biopharma, Kyowa Kirin

Innovative Online Notary Services Offered by Ronary Transforming Notarial Practices in Florida

Innovative Online Notary Services Offered by Ronary Transforming Notarial Practices in Florida
As online notarization continues to gain popularity, Ronary remains committed to upholding the highest standards of professionalism, integrity, and customer service. By harnessing the power of technology and education, the company is reshaping the way notarial services are delivered, making them more accessible, efficient, and convenient than ever before.

Miami, Florida – February 22, 2024 – Ronary, a pioneering company specializing in online notary services, is revolutionizing the landscape of notarial practices in Florida. With a commitment to efficiency, accessibility, and security, Ronary is leading the way in facilitating remote online notarization across the Sunshine State.

In response to the growing demand for remote notary services, Ronary has introduced a suite of innovative solutions tailored to meet the needs of modern businesses and individuals alike. Through their platform, clients can seamlessly access online notary services from the comfort of their homes or offices, eliminating the need for in-person appointments and streamlining the notarization process.

One of the key offerings by Ronary is their cutting-edge Ron Notary platform, which enables users to securely notarize documents online in compliance with Florida state regulations. This platform leverages advanced encryption technologies and identity verification protocols to ensure the integrity and authenticity of each notarized document.

Furthermore, Ronary is committed to promoting education and professional development within the notary industry. As part of their comprehensive services, the company offers the Florida Notary Course, equipping aspiring notaries with the knowledge and skills needed to excel in their profession. Through this course, participants gain a deep understanding of notarial laws, best practices, and ethical standards, empowering them to serve their clients with confidence and competence.

Video Link: https://www.youtube.com/embed/k1YRx3ATLqM

About Ronary:

Ronary is a leading provider of online notary services based in Miami, Florida. Committed to innovation and excellence, the company offers a range of solutions designed to streamline the notarization process and enhance accessibility for clients across the state. With their Ron Notary platform and Florida Notary Course, Ronary is empowering individuals and businesses to navigate the complexities of notarial practices with ease and confidence.

Media Contact
Company Name: Ronary
Contact Person: Jason B. Giller
Email: Send Email
Phone: +1 321-329-8447
Address:1111 Brickell Avenue, Suite 1550
City: Miami
State: Florida
Country: United States
Website: https://ronary.com

Medicare Agent Central Surpasses 150 Agent Milestone, Enhancing Access to Medicare Plans for Seniors Nationwide

Chagrin Falls, OH – Medicare Agent Central, a premier online directory dedicated to connecting seniors with professional health insurance agents specializing in Medicare plans, is proud to announce a significant milestone in its mission to provide comprehensive Medicare assistance. The directory now features over 150 agents, marking a pivotal moment in its commitment to serving the senior community across the United States.

Located at 8584 E Washington St Suite 104 in Chagrin Falls, Ohio, Medicare Agent Central has grown into an essential resource for seniors seeking personalized, professional guidance in navigating the complex world of Medicare. This achievement underscores the directory’s dedication to ensuring that every senior has access to the knowledge and expertise required to make informed decisions about their health insurance needs.

“Our goal has always been to simplify the process of finding the right Medicare plan by connecting seniors with knowledgeable and experienced agents in their area,” said a spokesperson for Medicare Agent Central. “Reaching over 150 agents in our directory is not just a number—it’s a testament to the trust and reliability we’ve built within the community. We’re dedicated to continuing our mission of providing a valuable resource that can make a significant difference in the lives of seniors nationwide.”

Medicare Agent Central offers a user-friendly platform where seniors can easily find health insurance agents who specialize in Medicare plans. The directory is designed to help users locate agents based on their specific needs and geographic location, ensuring a perfect match between the senior and the agent. With this comprehensive approach, Medicare Agent Central empowers seniors to make confident choices about their Medicare options.

As the demand for clear and accessible Medicare information grows, Medicare Agent Central remains at the forefront of providing seniors with the resources they need to navigate their health insurance options effectively. The directory’s continued growth and the increasing number of professional agents listed are a clear indication of its success and the crucial role it plays in the community.

Seniors and their families are encouraged to visit www.medicareagentcentral.com to explore the directory and learn more about how Medicare Agent Central can assist in finding the right Medicare plan with the help of a professional agent.

For further information, please contact:

Medicare Agent Central
8584 E Washington St Suite 104
Chagrin Falls, OH 44023
Phone: 440-409-7595
Email: admin@medicareagentcentral.com

About Medicare Agent Central

Medicare Agent Central is a leading online directory designed to connect seniors with professional health insurance agents specializing in Medicare plans. With a focus on accessibility and personalized service, Medicare Agent Central aims to simplify the process of choosing Medicare options, ensuring seniors have the information and support they need to make informed decisions about their healthcare coverage.

Media Contact
Company Name: Medicare Agent Central
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: www.medicareagentcentral.com

Post-Traumatic Stress Disorder Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Merck KGaA, Pfizer Inc.

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Post-Traumatic Stress Disorder pipeline constitutes 20+ key companies continuously working towards developing 22+ PTSD treatment therapies, analysis of Clinical Trials, Therapies, MOA, ROA, and Developments analyzes DelveInsight.

The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Post-Traumatic Stress Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Traumatic Stress Disorder Market.

 

Some of the key takeaways from the Post-Traumatic Stress Disorder Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Post-Traumatic Stress Disorder treatment therapies with a considerable amount of success over the years. 
  • Post-Traumatic Stress Disorder companies working in the treatment market are Bionomics Limited, Alto Neuroscience, Jazz Pharmaceuticals, Lundbeck, Atai Life Sciences, Aptinyx, Otsuka Pharmaceuticals, and others, are developing therapies for the Post-Traumatic Stress Disorder treatment 
  • Emerging Post-Traumatic Stress Disorder therapies in the different phases of clinical trials are- BNC210, ALTO-100, JZP150, Lu AG06466, EMP-01, NYX-783, Brexpiprazole, and others are expected to have a significant impact on the Post-Traumatic Stress Disorder market in the coming years.   
  • In Feb 2024, Curavit Clinical Research, a virtual contract research organization (VCRO) with expertise in decentralized clinical trials (DCTs) for digital therapeutics (DTx), effectively concluded a decentralized trial related to the Sana Device. Sana has forwarded the trial data for evaluation by the U.S. Food and Drug Administration (FDA) with the aim of obtaining Breakthrough Device Designation for its innovative wearable, virtual-reality-style mask. This device utilizes audiovisual stimulation to alleviate symptoms associated with post-traumatic stress disorder (PTSD).
  • In May 2022, Madrigal Mental Care unveiled its nanotechnology aimed at addressing post-traumatic stress disorder (PTSD) treatment and prevention during the Biomed Israel event.
  • In January 2022, Mydecine Innovations Group Inc. established a collaboration with Combat Stress and King’s College London to incorporate psilocybin within psychoactive-assisted psychotherapy, targeting the treatment of post-traumatic stress disorder (PTSD) specifically in veterans.

 

Post-Traumatic Stress Disorder Overview

Post-Traumatic Stress Disorder (PTSD) is a mental health condition that can develop after experiencing or witnessing a traumatic or distressing event. These events could involve threats of injury or death, serious accidents, natural disasters, combat, physical assault, or other life-threatening situations.

 

Get a Free Sample PDF Report to know more about Post-Traumatic Stress Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-pipeline-insight

 

Emerging Post-Traumatic Stress Disorder Drugs Under Different Phases of Clinical Development Include:

  • Lu AG06466: Lundbeck
  • EMP-01: Atai Life Sciences
  • BNC210: Bionomics Limited
  • ALTO-100: Alto Neuroscienc
  • JZP150: Jazz Pharmaceuticals
  • NYX-783: Aptinyx
  • Brexpiprazole: Otsuka Pharmaceuticals

 

Post-Traumatic Stress Disorder Route of Administration

Post-Traumatic Stress Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous

 

Post-Traumatic Stress Disorder Molecule Type

Post-Traumatic Stress Disorder Products have been categorized under various Molecule types, such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine

 

Post-Traumatic Stress Disorder Pipeline Therapeutics Assessment

  • Post-Traumatic Stress Disorder Assessment by Product Type
  • Post-Traumatic Stress Disorder By Stage and Product Type
  • Post-Traumatic Stress Disorder Assessment by Route of Administration
  • Post-Traumatic Stress Disorder By Stage and Route of Administration
  • Post-Traumatic Stress Disorder Assessment by Molecule Type
  • Post-Traumatic Stress Disorder by Stage and Molecule Type

 

DelveInsight’s Post-Traumatic Stress Disorder Report covers around 22+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Post-Traumatic Stress Disorder product details are provided in the report. Download the Post-Traumatic Stress Disorder pipeline report to learn more about the emerging Post-Traumatic Stress Disorder therapies

 

Some of the key companies in the Post-Traumatic Stress Disorder Therapeutics Market include:

Key companies developing therapies for Post-Traumatic Stress Disorder are – Merck KGaA, Pfizer Inc., Aurobindo Pharma, GlaxoSmithKline plc, Jazz Pharmaceuticals, Mydecine Innovations Group, Tonix Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Lupin Limited, Teva Pharmaceutical, Viatris Inc., Jubilant Pharmova, and others.

 

Post-Traumatic Stress Disorder Pipeline Analysis:

The Post-Traumatic Stress Disorder pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
  • Post-Traumatic Stress Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Post-Traumatic Stress Disorder drugs and therapies

 

Post-Traumatic Stress Disorder Pipeline Market Drivers

  • Increase in prevalence, increased initiatives to create public awareness and knowledge of disease are some of the important factors that are fueling the Post-Traumatic Stress Disorder Market.

 

Post-Traumatic Stress Disorder Pipeline Market Barriers

  • However, heterogeneity of the symptoms, delayed-onset PTSD and other factors are creating obstacles in the Post-Traumatic Stress Disorder Market growth.

 

Scope of Post-Traumatic Stress Disorder Pipeline Drug Insight    

  • Coverage: Global
  • Key Post-Traumatic Stress Disorder Companies: Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Lundbeck, Atai Life Sciences, Aptinyx, Otsuka Pharmaceuticals, and others
  • Key Post-Traumatic Stress Disorder Therapies: BNC210, ALTO-100, JZP150, Lu AG06466, EMP-01, NYX-783, Brexpiprazole, and others
  • Post-Traumatic Stress Disorder Therapeutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
  • Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers 

 

Request for Sample PDF Report for Post-Traumatic Stress Disorder Pipeline Assessment and clinical trials

 

Table of Contents

1. Post-Traumatic Stress Disorder Report Introduction

2. Post-Traumatic Stress Disorder Executive Summary

3. Post-Traumatic Stress Disorder Overview

4. Post-Traumatic Stress Disorder- Analytical Perspective In-depth Commercial Assessment

5. Post-Traumatic Stress Disorder Pipeline Therapeutics

6. Post-Traumatic Stress Disorder Late Stage Products (Phase II/III)

7. Post-Traumatic Stress Disorder Mid Stage Products (Phase II)

8. Post-Traumatic Stress Disorder Early Stage Products (Phase I)

9. Post-Traumatic Stress Disorder Preclinical Stage Products

10. Post-Traumatic Stress Disorder Therapeutics Assessment

11. Post-Traumatic Stress Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Post-Traumatic Stress Disorder Key Companies

14. Post-Traumatic Stress Disorder Key Products

15. Post-Traumatic Stress Disorder Unmet Needs

16 . Post-Traumatic Stress Disorder Market Drivers and Barriers

17. Post-Traumatic Stress Disorder Future Perspectives and Conclusion

18. Post-Traumatic Stress Disorder Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Post-Traumatic Stress Disorder Pipeline Assessment | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Merck KGaA, Pfizer Inc.

PSB Announces the M4U TWM Earbuds Are Now Shipping

The new wireless in-ears employ hybrid planar technology and an integration with Audiodo for a seriously personalized listening experience

PICKERING, ONTARIO – PSB Speakers, one of the first premium hi-fi loudspeaker brands to enter the headphone market over 10 years ago, announces the M4U TWM earbuds are now available for purchase. The headphones originally announced at Axpona 2023 feature improved engineering, better componentry with stunning presentation of musical detail implement. Additionally, through a partnership with Audiodo Personal Sound™ the user can setup sound personalization options along with PSB’s proprietary RoomFeel™ technology. The new wireless in-ear headphones are available to purchase for US$199 / CA$299.

True Wireless Micro Planar Earphones

The M4U TWM earbuds leverage powerful Magneto-Static technology in a Hybrid Planar dual driver design, utilizing the same technology found in high-end magneto loudspeakers and fitting them into remarkably compact earbuds. Dedicated transducers, one for high frequencies and one for low frequencies work together to make the in-ear listening experience truly pristine, reproducing sound with crisp highs, natural midrange and deep lush bass. Enhanced aptX™ Adaptive Bluetooth technology keeps everything in sync from movies to games with dynamic low latency and an adaptive bit rate supporting up to 24-bit high- definition audio quality.

With an IP65 rating the M4U TWM are sweatproof, water resistant and dustproof making them well-suited for active audiophiles to use in the gym, during cycling or running and even on a long commute. Convenient features like hard click buttons on both earphones make music control and voice calls hands-free and intuitive, while a smart USB-C charging case delivers a maximum of 32 hours of extended play time (8 hours out of the case and 3 additional charge cycles in the case).

Sound Optimization with Audiodo Personal Sound™

An integration with Audiodo Personal Sound™ technology is one of the most unique features offered in both wireless headphones. The breakthrough technology uses a non-replicable set of algorithms which allows listeners to calibrate their headphones in a way that accommodates for the listening qualities of their left and right ears independently. After completing a quick and easy hearing assessment accessed through the PSB Headphones app, Audiodo Personal Sound™ maps out a precise and thorough understanding of the listener’s hearing, calculates what changes need to be made based on personal sound perception, and formulates a compensation curve for the listener that can be applied to the overall headphone sound.

Natural RoomFeel™ Tuning

Created to deliver rich and natural sound through headphones, the next generation of PSB’s proprietary RoomFeel technology mimics the experience of listening to a pair of high-quality, full-range speakers properly set up in a good room. Carefully developed using research and expertise around ‘Room Gain’ – the energy and warmth that room boundaries add to the response curve of a flat-measuring loudspeaker, RoomFeel makes the music feel less ‘in the head’ by recreating an open and natural in-room listening experience through the M4U headphones.

PSB Headphones App

All headphone settings, including Audiodo Personal Sound™ tests and Transparency modes are accessed centrally through the PSB Headphones app, a full-featured app that allows users to adjust settings, check battery levels and regularly keep the headphones up-to-date with the latest firmware updates and codes.

Image showing M4U TWM earbuds inside smart charging case

Key Features of the M4U TWM

  • Wireless auto-pairing with any Bluetooth™ enabled device
  • Qualcomm aptX Adaptive Bluetooth™
  • Magneto-Static, Hybrid Planar dual driver design
  • Lightweight, secure fit suits any active lifestyle
  • Activate voice assistants or use hard click buttons for hands-free calling and music control
  • Rechargeable with 8 hours of playback and 24 hours in the smart charging case for 32 hours of total extended play time
  • IP65 rated for protection against sweat, dust and weather
  • RoomFeel™, Audiodo™ and cVc™ (clear voice capture) technologies built-in
  • 3 sizes of silicon tips for customizable fit

About PSB Speakers

Since 1972, Founder and Chief Designer, Paul Barton, has been cementing his legacy as an expert in designing and building high-fidelity speakers that incorporate scientific principles in psychoacoustics. More than 50 years later and now a strategic part of Lenbrook International’s global portfolio, PSB Speakers’ products are sold in more than 70 markets where the brand sets the standard for “True to Nature” sound and is critically acclaimed for its value-driven and non-fatiguing speaker design. With an expansive suite of products that include audiophile speakers, ANC headphones, powerful and musical subwoofers, and a family of installed speaker solutions, PSB Speakers is designed and built to bring life to recorded music at world class levels.

Media Contact
Company Name: PSB Speakers
Contact Person: June Ip
Email: Send Email
City: Pickering
State: ON
Country: Canada
Website: https://psbspeakers.com